Biotechnology body Celgene Corp claimed to have received the approval of U.S. health regulators for human testing of stem cell therapy. The therapy will be applied on an experimental basis to the Crohn’s disease.

The company said clinical development of PDA001, its therapy utilizing human placenta-derived stem cells, would start by the end of the year.

Source: Reuters